ArticleNature2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers.
0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
238 citing papers in PubMed.
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Nature medicine · 2026Trial
- A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Glecirasib in KRASNature medicine · 2025Trial
- M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.Oncogene · 2026Article
- Article
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.Experimental hematology & oncology · 2026Review
- A Versatile DNA-Encoded Library Platform for the Discovery of Highly Cooperative Chemical Inducers of Proximity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cell type-selective targeting by heterobifunctional protein binders via in-cell enrichment.Nature communications · 2026Article
- Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.Research square · 2026Article
- Aporphine AlkaloidPharmaceuticals (Basel, Switzerland) · 2026Article
- KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.Science advances · 2026Article
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Discovery of TCR-like antibodies to the KRAS G12D neoantigen via in silico-in vitro workflow.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity.Cancer immunology research · 2026Article
- RAS-targeted therapies for pancreatic cancer.ESMO gastrointestinal oncology · 2026Review
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Cancer research · 2026Article
178 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
53 authors.
Matthew HolderfieldRevolution Medicines, Redwood City, CA, USA.
Bianca J LeeRevolution Medicines, Redwood City, CA, USA.
Jingjing JiangRevolution Medicines, Redwood City, CA, USA.
Aidan TomlinsonRevolution Medicines, Redwood City, CA, USA.
Kyle J SeamonRevolution Medicines, Redwood City, CA, USA.
Alessia MiraDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Enrico PatruccoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Grace GoodhartDepartment of Surgery, University of Cincinnati, Cincinnati, OH, USA.ORCID 0009-0004-8549-8852
Julien DillyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4006-5285
Yevgeniy GindinRevolution Medicines, Redwood City, CA, USA.
Nuntana DinglasanRevolution Medicines, Redwood City, CA, USA.
Yingyun WangRevolution Medicines, Redwood City, CA, USA.
Lick Pui LaiRevolution Medicines, Redwood City, CA, USA.
Shurui CaiRevolution Medicines, Redwood City, CA, USA.
Lingyan JiangRevolution Medicines, Redwood City, CA, USA.
Nicole NasholmRevolution Medicines, Redwood City, CA, USA.ORCID 0000-0002-5451-4985
Nataliya ShifrinRevolution Medicines, Redwood City, CA, USA.
Cristina BlajRevolution Medicines, Redwood City, CA, USA.
Harshit ShahRevolution Medicines, Redwood City, CA, USA.
James W EvansRevolution Medicines, Redwood City, CA, USA.
Nilufar MontazerRevolution Medicines, Redwood City, CA, USA.
Oliver LaiRevolution Medicines, Redwood City, CA, USA.
Jade ShiRevolution Medicines, Redwood City, CA, USA.
Ethan AhlerRevolution Medicines, Redwood City, CA, USA.
Elsa QuintanaRevolution Medicines, Redwood City, CA, USA.
Stephanie ChangRevolution Medicines, Redwood City, CA, USA.
Anthony SalvadorRevolution Medicines, Redwood City, CA, USA.
Abby MarquezRevolution Medicines, Redwood City, CA, USA.
Jim CreggRevolution Medicines, Redwood City, CA, USA.
Yang LiuRevolution Medicines, Redwood City, CA, USA.
Anthony MilinRevolution Medicines, Redwood City, CA, USA.
Anqi ChenRevolution Medicines, Redwood City, CA, USA.
Tamar Bar ZivRevolution Medicines, Redwood City, CA, USA.ORCID 0009-0008-1751-8507
Dylan ParsonsRevolution Medicines, Redwood City, CA, USA.
John E KnoxRevolution Medicines, Redwood City, CA, USA.
Jennifer E KlompLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jennifer RothBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-5117-5586
Matthew ReesBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2987-7581
Melissa RonanBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-4269-1404
Antonio Cuevas-NavarroHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6208-6944
Feng HuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9605-7594
Piro LitoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2196-3503
David SantamariaMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain.
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0701-6203
Andrew M WatersDepartment of Surgery, University of Cincinnati, Cincinnati, OH, USA.ORCID 0000-0002-6058-5878
Channing J DerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-7751-2747
Chiara AmbrogioDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.ORCID 0000-0003-4122-701X
Zhengping WangRevolution Medicines, Redwood City, CA, USA.
Adrian L GillRevolution Medicines, Redwood City, CA, USA.
Elena S KoltunRevolution Medicines, Redwood City, CA, USA.
Jacqueline A M SmithRevolution Medicines, Redwood City, CA, USA. jan@revmed.com.ORCID 0000-0001-5028-8725
David WildesRevolution Medicines, Redwood City, CA, USA. pete@revmed.com.ORCID 0009-0009-3855-7270
Mallika SinghRevolution Medicines, Redwood City, CA, USA. msingh@revmed.com.ORCID 0009-0003-0234-1589
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Alexander Drilon, Piro Lito · 2007 to 2026
$31.2MIntegrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7MSToP Cancer SPORE: Developmental Research ProgramP50CA257911 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jen Jen Yeh · 2022 to 2026
$12.9MTargeting undruggable RAS for cancer treatmentR35CA232113 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2018 to 2024
$6.3MDissecting KRAS oncoprotein signaling with small molecule inhibitorsR01CA230745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2018 to 2026
$3.8MMechanisms of response and resistance to KRAS inhibition in pancreatic cancerR01CA276268 · NCI · DANA-FARBER CANCER INST · PI Andrew James Aguirre · 2023 to 2026
$2.2MMechanisms of adaptation and resistance to emerging therapies for lung cancerR01CA279264 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2023 to 2026
$2.0MIdentification of resistance mechanisms to direct KRAS inhibition in pancreatic cancerK22CA276632 · NCI · UNIVERSITY OF CINCINNATI · PI WATERS, ANDREW M · 2023 to 2025
$576kMechanistic Basis for ERK in driving KRAS-dependent pancreatic cancerR00CA276700 · NCI · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI Jennifer E Klomp · 2025 to 2026
$416kMechanistic Basis for ERK in driving KRAS-dependent pancreatic cancerK99CA276700 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KLOMP, JENNIFER E · 2023 to 2024
$223kDefining the roles of ERK MAPK in driving KRAS-mutant pancreatic cancer growth.F32CA239328 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KLOMP, JENNIFER E · 2019 to 2020
$72kNCI NIH HHS F32 CA239328NCI NIH HHS K22 CA276632NCI NIH HHS K99 CA276700NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA257911NCI NIH HHS R00 CA276700NCI NIH HHS R01 CA230745NCI NIH HHS R01 CA276268NCI NIH HHS R01 CA279264NCI NIH HHS R35 CA232113NCI NIH HHS T32 CA009156
Abstract
RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 61
Indexed as
Antineoplastic AgentsMutationNeoplasmsOncogene Protein p21(ras)PiperazinesProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorGTP PhosphohydrolasesGuanosine TriphosphateHumansMembrane ProteinsMiceMice, Inbred BALB CMice, Inbred C57BLSignal TransductionAntineoplastic AgentsGTP PhosphohydrolasesGuanosine TriphosphateHRAS protein, humanKRAS protein, humanMembrane ProteinsNRAS protein, humanOncogene Protein p21(ras)PiperazinesProto-Oncogene Proteins p21(ras)RAS Inhibitor A122RMC-7977
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.